Morphine Tolerance Increased Cannabinoid Catalepsy Without Matching Temperature Enhancement in Mice

A 1987 mouse study found greater cannabinoid-induced catalepsy after morphine tolerance without comparable enhancement of hypothermia. The same drug history could produce hypersensitivity on one endpoint and a different pattern on another.

Several cannabinoid structures were compared

The experiment included delta-8 THC and two epoxyhexahydrocannabinol forms. Prior tolerance to some, but not all, cannabinoid conditions reduced sensitivity to morphine-related cooling. Chemical similarity therefore did not guarantee identical transfer.

The reverse direction was also selective

Morphine-tolerant mice showed partial temperature cross-tolerance to one tested analogue but not the others. At the same time, cataleptogenic effects of all the tested cannabinoids were enhanced. These results should not be condensed into a single statement of reduced cannabinoid sensitivity.

Latent cross-tolerance was an interpretation

The authors discussed a possible latent temperature cross-tolerance. That proposal does not override the directly reported positive and null comparisons or establish a universal mechanism. Catalepsy is also a specific animal movement state, not a direct measure of subjective intoxication.

The study supports considering hypersensitivity alongside tolerance when assessing a later drug challenge. It does not predict how an opioid-tolerant patient responds to cannabis or establish protection from impairment. Endpoint, analogue identity and pretreatment direction are inseparable from its conclusion.

Related: interpreting cannabis tolerance claims.

Research cited

Narimatsu S; Yamamoto I; Watanabe K; Yoshimura H. Change in hypothermia and catalepsy induced by cannabinoids or morphine in mice tolerant to these substances. European journal of pharmacology (1987). doi:10.1016/0014-2999(87)90562-0. Findings discussed from the study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

A 2026 Cannabis Review Explains Why Potency, Placebo Response and Sedation Need Separate Measures

A 2026 narrative review argues that product potency is not the same as delivered THC dose and that placebo responses remain important among experienced users. Its laboratory framework also distinguishes reduced drug reinforcement from nonspecific sedation. Users can change how they inhale The review notes that participants alter inhalation patterns…

Spread the love

Read Article: A 2026 Cannabis Review Explains Why Potency, Placebo Response and Sedation Need Separate Measures

THC Antinociception Persisted Without the Same Dynorphin Signal in Tolerant Rats

A 1999 rat study found that tolerance weakened THC-related modulation of spinal dynorphin, while antinociception could still occur without the same elevated dynorphin measure. The role of a downstream signal changed with dose and adaptive state. The experiment examined spinal responses The work followed earlier findings linking acute intrathecal THC…

Spread the love

Read Article: THC Antinociception Persisted Without the Same Dynorphin Signal in Tolerant Rats

A Passiflora-Derived Fraction Reduced THC Withdrawal Signs in a Mouse Model

A 2002 mouse experiment reported fewer antagonist-precipitated withdrawal signs with a Passiflora-derived benzoflavone fraction. The finding concerns a defined experimental preparation and animal model, not a demonstrated treatment for cannabis-use disorder in people. Concurrent and acute interventions were tested Mice received repeated oral THC with or without the fraction. A…

Spread the love

Read Article: A Passiflora-Derived Fraction Reduced THC Withdrawal Signs in a Mouse Model

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us